HUTCHMED (China) Limited

HCM · AIM · Health Care · mcap £1,764m · 215.0p

Beta Briefing, track record and signals & risks are not ready for HUTCHMED (China) Limited yet.

We follow 967 UK small caps and every one of their announcements – often hundreds per company. 71 companies are already wired into a briefing: browse them.

Share price & announcements

6M 1Y 3Y

Ask about HUTCHMED (China) Limited Beta

Answered by AI only from HCM’s own announcements, every statement linked to its source. Free with an account – no password, just a link. Not investment advice.

Key financials · LTM

All financials →

Market cap: £1.9bn
EV: –
Net cash: –
Revenue: –
EBITDA: –
Shares: 872.3m +0.0%

What's new

Monitoringlast checked today, 11:41All RNS →

29 Sep
Submission of US NDA for ORPATHYS® plus TAGRISSO
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
28 Sep
HUTCHMED Initiates Global Trial of HMPL-A830
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
24 Sep
Data to be Presented at ESMO 2026
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
3 Sep
HUTCHMED Licenses KRAS-EGFR-Antibody to GSK
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
1 Sep
SANOVO trial demonstrated significant PFS benefit
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing...

Company filings. Not investment advice.